QoL · men and women aged over 18 years with chronic fatigue syndrome
The review found no eligible studies for this question.
2 findings from 1 review
Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins
1 finding from 1 review
Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins
Laser plus sclerotherapy showed no clear difference in adverse events ‐ Hyperpigmentation ( compared with sclerotherapy (low certainty).
1 finding from 1 review
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Laser plus sclerotherapy showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (low certainty).
1 finding from 1 review
Pain ( · people with telangiectasias and reticular veins
Laser plus sclerotherapy may leads to higher pain ( compared with sclerotherapy (low certainty).
1 finding from 1 review
Recurrence · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to resolution · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · DCM (non‐ischaemic)
It is very uncertain whether stem cell therapy changes all‐cause mortality compared with control (very low certainty).
1 finding from 1 review
Procedural complications · DCM (non‐ischaemic)
1 finding from 1 review
Health‐related quality of life · DCM (non‐ischaemic)
1 finding from 1 review
Functional capacityAssessed: 6MWT · DCM (non‐ischaemic)
1 finding from 1 review
Performance status – change in functional class (NYHA) · DCM (non‐ischaemic)
1 finding from 1 review
MACE · DCM (non‐ischaemic)
1 finding from 1 review
Ventricular arrhythmias (within 30 days) · DCM (non‐ischaemic)
1 finding from 1 review
Overall survival ‐ first‐line studies · glioblastoma in adults
Anti‐EGFR therapy showed no clear difference in overall survival ‐ first‐line studies compared with placebo or standard of care (moderate certainty).
1 finding from 1 review
Overall survival ‐ recurrent disease studies · glioblastoma in adults
Anti‐EGFR therapy showed no clear difference in overall survival ‐ recurrent disease studies compared with placebo or standard of care (low certainty).
1 finding from 1 review
Lymphopenia · glioblastoma in adults
Anti‐EGFR therapy showed no clear difference in lymphopenia compared with placebo or standard of care (low certainty).
1 finding from 1 review
Neutropenia · glioblastoma in adults
Anti‐EGFR therapy showed no clear difference in neutropenia compared with placebo or standard of care (low certainty).
1 finding from 1 review
Thrombocytopenia · glioblastoma in adults
Anti‐EGFR therapy showed no clear difference in thrombocytopenia compared with placebo or standard of care (low certainty).
1 finding from 1 review